Tracks outcomes and side effects in people with sarcoma or gastrointestinal cancer
Observes outcomes and side effects in adults with sarcoma or gastrointestinal cancer receiving standard treatment.
Plain-language title generated from the registry record
Registry title: Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
Key facts
- Where
- Chapel Hill, United StatesSee the site
Where in United States
- University of North Carolina at Chapel Hill, Department of Radiation OncologyChapel Hill, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- UNC Lineberger Comprehensive Cancer Center
- Trial code
- NCT05743426
- Record updated
- 30 March 2026
- Original description
This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy.Read full original descriptionShow less
Disease Outcomes and Toxicities in Patients With Gastrointestinal and Sarcomatous Malignancies
This prospective, single-institution, observational study explores disease outcomes and toxicities in subjects with gastrointestinal malignancies and sarcoma (bone and soft tissue) who are being treated with standard-of-care therapies including radiotherapy.
Recent advances in treatment approaches affected disease outcomes and toxicities. Prospective monitoring of disease outcomes and toxicities using standardized assessments will provide information about recent changes in the standard of care and further refine treatment approaches and prospective clinical trial design.
Inclusion: In order to participate in this study a subject must meet all of the eligibility criteria outlined below; Subject is willing and able to provide written informed consent to participate in the study and HIPAA authorization for the release of personal health information. Subjects are willing and able to comply with study procedures based on the judgment of the investigator or protocol designer; Age ≥ 18 years at the time of consent; Histological, cytological, or radiographic evidence/confirmation of a gastrointestinal malignancy or sarcoma; Females with childbearing potential and male subjects with fathering potential are allowed to participate in this study.
Exclusion: All subjects meeting any exclusion criteria at baseline will be excluded from study participation; Inability or unwillingness to provide informed consent; Patients who state they do not expect to be available or willing to follow up at expected intervals post-treatment.